Description
Blood, NA, Fasting or Non Fasting: As suggested by doctor
Sample Required:
The sample required for the IHC Single Marker (ER) Test is typically a tissue biopsy specimen. This specimen is collected from the patient and is commonly obtained during procedures such as a breast biopsy.
Test Time:
The test time can vary depending on the laboratory’s processing time and the complexity of the case. Results may be available in a few days to a couple of weeks.
Test Normal Range:
The IHC Single Marker (ER) Test does not have a “normal range” like some blood tests. Instead, it assesses the presence or absence of estrogen receptor (ER) proteins within tissue samples.
What is the Test?
The IHC Single Marker (ER) Test is a specialized immunohistochemistry (IHC) laboratory test used to detect and visualize estrogen receptor (ER) proteins within tissue samples. It is commonly utilized in breast cancer diagnosis and treatment planning. The test helps determine whether the cancer cells in a breast tumor have estrogen receptors.
Test Procedure:
A tissue biopsy sample, often from a breast tumor, is collected from the patient. The tissue sample is processed, embedded in paraffin wax, and cut into thin sections. These sections are placed on slides and treated with specific antibodies that bind to estrogen receptor (ER) proteins. Chemical reactions are used to visualize the binding of antibodies to ER proteins. The tissue sections are examined under a microscope to assess the presence and distribution of ER proteins.
When to Take the Test:
The IHC Single Marker (ER) Test is typically ordered by a healthcare provider when a patient has a breast biopsy or tissue sample from another site that needs further examination. It helps guide treatment decisions for breast cancer.
Who Should Take This Test:
Patients with breast tumors or suspected breast cancer may have this test performed if their healthcare provider believes it is necessary for diagnosis or treatment planning.
Precautions for Exceptional Cases:
In exceptional cases, such as pregnancy, the decision to perform the IHC Single Marker (ER) Test will depend on the specific medical situation and the recommendations of the healthcare provider. It’s essential to discuss any concerns or potential risks with the healthcare team.
FAQs (Frequently Asked Questions):
Q1: What does a positive ER result mean in breast cancer testing?
A: A positive result indicates that estrogen receptors (ER) are present on the cancer cells. This may suggest that hormone therapy, which targets ER-positive cells, could be a suitable treatment option.
Q2: What if my breast cancer is ER-negative?
A: An ER-negative result means that estrogen receptors are not present on the cancer cells. In this case, hormone therapy targeting ER may not be effective, and other treatment options will be considered.
Q3: Are there any risks associated with the IHC Single Marker (ER) Test?
A: The test itself is low-risk. However, there may be risks associated with the biopsy or surgical procedure used to collect the tissue sample, which should be discussed with the healthcare provider.
Q4: Can this test definitively diagnose breast cancer?
A: While the IHC Single Marker (ER) Test is an essential component of breast cancer diagnosis and treatment planning, a definitive diagnosis often requires a combination of tests, including histopathology, imaging, and clinical assessment.
Q5: How do I prepare for the IHC Single Marker (ER) Test?
A: Preparation typically involves discussing the procedure with your healthcare provider and following any pre-test instructions they provide. This may include fasting before the biopsy procedure or discontinuing certain medications temporarily.
